Clareo Health | Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
Prediabetes or Diabetes according to the Guideline of the American Diabetes Association (HbA1c \>5,7 percent, or fasting glucose values \> 100 mg/dL, or glucose levels \> 140 mg/dL at 2h during an oral glucose tolerance test)
Being overweight (Body Mass Index \> 25.0 kg/m²)
Being able to independently:
\- Perform measurements of blood glucose and ketone levels
\- Use a continous glucose monitor
\- Contact the study team
You may not be if
Patients who are allergic to SGLT-2-Inhibitors
Patients with autoimmune diabetes (Typ 1 or LADA)
Patients with pancreoprivic diabetes
Patients with a history of ketoacidosis or lactate acidosis
Patients with severe hypoglycemic episodes in the 6 moths prior to inclusion
Patients with bariatric surgery (in the past or planed)
Patients with nephritic range proteinuria (\>3,5g of Albumin/day)
